KIMSKrishna Institute of Medical Sciences Ltd
KIMS Q1FY27: consolidated PAT down 56% YoY on expansion costs, revenue up 35%
hospitals · healthcare · margin compression
Research Reports
03 Aug 2026
DRAGARWQDR.AGARWALS EYE HOSPITAL LTD.-$
Standalone PAT up 35% YoY to ₹23.4 Cr on 33% lower finance costs; revenue +22%
eye care · hospital chain · net margin expansion
ARTEMISMEDArtemis Medicare Services Ltd
Artemis Medicare Q1 FY27: consolidated PAT +48% YoY on margin expansion to 19.6% OPM
hospitals · healthcare services · margin expansion
GPTHEALTHGPT Healthcare Ltd
GPT Healthcare Q1FY27: standalone PAT +65.7% YoY on margin expansion, revenue up 17.8%
hospitals · healthcare services · margin expansion
KAYAKaya Ltd
Kaya Q1 FY27: standalone loss widens 8% YoY to ₹15.2 Cr despite 14% revenue growth
skin care · hair care · standalone loss
PARKHOSPSPark Medi World Ltd
Park Medi World Q1: consolidated PAT ₹88.6 Cr up 35% YoY as new hospitals scale
hospitals · healthcare services · bed capacity expansion
ASTERDMAster DM Healthcare Ltd
First quarter of merged healthcare giant: focus on integration execution and synergy ramp
healthcare · merger · integration
SAILIFESai Life Sciences Ltd
Q1 FY27: Capex Drag & Margin Pressure — What to Expect From India's CDMO Champion
CDMO · capex · EBITDA margins
EMCUREEmcure Pharmaceuticals Ltd
Margin Play on Biologics — Emcure Q1 FY27 in Focus
biosimilars · margin expansion · Gennova
LUPINLUPIN LTD.
Growth off a modest base, catalyzed by US product momentum
revenue growth · US FDA approvals · margin trajectory
02 Aug 2026
SANOFISanofi India Ltd
Diabetes Momentum Under Spotlight as Sanofi India Reports Q1
diabetes growth · insulin portfolio · margins
GLAXOGLAXOSMITHKLINE PHARMACEUTICALS LTD.
GSK India's Specialty Pivot: Can Q1 Sustain the FY27 Double-Digit Promise?
oncology · specialty medicines · vaccines
BIOCONBIOCON LTD.
Recovery Test: Can BIOCON Restore Margins After Q3 Loss?
margin recovery · BBL consolidation · biosimilar momentum
AUROPHARMAAUROBINDO PHARMA LTD.
Margin pivot and US consolidation: Aurobindo targets 21% EBITDA in FY27
margin recovery · US expansion · Lannett integration
01 Aug 2026
31 Jul 2026
NHNarayana Hrudayalaya Ltd
Narayana Q1: consol revenue +78% on UK buyout, but margins squeeze PAT growth to just 5% YoY
hospitals · healthcare · margin compression
GLENMARKGLENMARK PHARMACEUTICALS LTD.
Glenmark Q1: revenue +23% YoY, consolidated PAT ₹483 Cr on a clean, exceptional-free quarter
pharmaceuticals · us generics · revenue growth
CONCORDBIOConcord Biotech Ltd
Concord Biotech's Q1 marks return to growth: consol PAT +31% YoY to ₹58 Cr, margins expand
pharmaceuticals · api · revenue rebound
SUNPHARMASUN PHARMACEUTICAL INDUSTRIES LTD.
Sun Pharma Q1: sales +10.5%, but EBITDA margin slips to 28.9% and adjusted PAT up only ~3%
specialty pharma · margin compression · us generics decline
STARStrides Pharma Science Ltd
Strides Q1 PAT ₹165 Cr up 57% YoY, but one-off Pivot Path gain masks flat core profit
pharma · us generics · exceptional gain
30 Jul 2026
INDGNIndegene Ltd
Indegene Q1: revenue up 40% YoY but consolidated PAT flat at ₹116 Cr on margin squeeze
life sciences commercialization · pharma outsourcing · healthcare
ALIVUSGlenmark Life Sciences Ltd
Alivus Q1 net profit up 32% YoY to ₹160 Cr as margins hit record ~33%
api · pharma · margin expansion
TORNTPHARMTORRENT PHARMACEUTICALS LTD.
Torrent Pharma revenue +55% on JB merger; consolidated PAT flat at ₹566 Cr as net margin compresses
pharma · jb pharma merger · acquisition-led growth
RAINBOWRainbow Children's Medicare Ltd
Rainbow Q1: consolidated revenue +33% YoY to ₹470 Cr; PAT +16% as margins compress on expansion
hospitals · healthcare · revenue growth
MEDANTAGlobal Health Ltd
Medanta Q1: revenue +26% YoY, consolidated PAT flat at Rs157 Cr as Noida ramp squeezes margins
hospitals · healthcare services · revenue growth
MANKINDMankind Pharma Ltd
Mankind Pharma Q1: consolidated PAT up 29% YoY to ₹574 Cr on EBITDA margin expansion
pharma · domestic formulations · margin expansion
AJANTPHARMAJANTA PHARMA LTD.
Ajanta Pharma Q1: consolidated PAT up 31% to ₹334 Cr on 25% revenue jump, US +57%
pharma · branded generics · us generics
AHCLAnlon Healthcare Ltd
Anlon Healthcare Q1 FY27: consolidated PAT ₹8.28 Cr, +134% YoY, margins dilute
api manufacturing · subsidiary consolidation · margin dilution
HESTERBIOHESTER BIOSCIENCES LTD.
Hester Q1: Consol PAT +459% on one-off gain, but adjusted profit falls ~34% YoY
animal health vaccines · poultry growth · one-off gain
29 Jul 2026
